Loading... Please wait...
Sort by:

FirstWord Generics/Biosimilar Reports

 

  • Pages:
  • 1
  • 2
  • Biosimilars: EU Payer Perspectives
    Learn More Biosimilars: EU Payer Perspectives
    Leading European payer experts reveal the real impact of biosimilars over the last 12 months Keeping track of the dynamics and nuances of the biosimilars market is critical – not least because the $232 billion...
  • Charting the Global Biosimilar Pipeline
    Learn More Charting the Global Biosimilar Pipeline
    There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche's Avastin (bevacizumab), Abbvie's Humira (adalimumab)...
  • Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle
    Learn More Commercialisation of Biosimilars: Team Tactics & Strategies Across the Product Lifecycle
    Commercialisation of Biosimilars From bench to bedside, biosimilars continue to dominate boardroom discussions around the world. But after all the talking, what's the secret to success in this high stakes market?...
  • Commercialisation of Biologics: Benchmarking leading players
    Learn More Commercialisation of Biologics: Benchmarking leading players
    Commercialisation of Biologics: Benchmarking Leading Players It’s clear that the rapidly growing biologics sector holds a wealth of promise. The significant opportunities resulting from breaking new ground are...
  • The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events
    Learn More The Future of Biosimilars in the USA: Mapping critical uncertainties and the impact of future events
    The Future of Biosimilars in the USA Can pharma resolve the litigation frenzy hampering biosimilars' market entry in the US? Is too much focus on legal wrangling stifling healthy competition and innovation? And, as the...
  • Biosimilars Real World Evidence: Proving the point
    Learn More Biosimilars Real World Evidence: Proving the point
    Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator...
  • The Future of Biosimilars in Europe
    Learn More The Future of Biosimilars in Europe
    Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...
  • Biosimilars in Emerging Markets (2017)
    Learn More Biosimilars in Emerging Markets (2017)
    Biosimilars: Make the most of high risk emerging market opportunities  Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...
  • Biosimilars: US Payer Perspectives (2017)
    Learn More Biosimilars: US Payer Perspectives (2017)
    Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…  Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...
  • The Future of Biobetters
    Learn More The Future of Biobetters
    Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...
  • Biosimilars: European Payer Perspectives (2017)
    Learn More Biosimilars: European Payer Perspectives (2017)
    What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...
  • Defending Against Biosimilars: Originator strategies
    Learn More Defending Against Biosimilars: Originator strategies
    Battle of the biologics: How to survive The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with...
  • Biosimilars Education: Addressing a significant unmet need
    Learn More Biosimilars Education: Addressing a significant unmet need
    How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? As the market expands and new therapeutic sectors come on stream, more...
  • Benchmarking Biologic Innovator Value-Added-Services
    Learn More Benchmarking Biologic Innovator Value-Added-Services
    Delivering high-quality value-added services for biologics What are the “beyond-the-pill” services that biologic companies need to deliver to ensure improved patient compliance and outcomes? Patient, payer...
  • The Future of Biosimilars 2016
    Learn More The Future of Biosimilars 2016
    Development activity is surging as the focus shifts to commercialisation. How will the market evolve? The race to commercialise biosimilars is on. What will it take to create a thriving market? Will payers see real cost...
  • Biosimilars: US Payer Perspectives (2016)
    Learn More Biosimilars: US Payer Perspectives (2016)
    Biosimilars have finally hit the US market. Now comes the hard part. The US Biosimilars market is open for business. What will it take to get customers in the door? Get our new report, Biosimilars: US Payer...
  • Biosimilars: European Payer Perspectives (2016)
    Learn More Biosimilars: European Payer Perspectives (2016)
    What’s driving the uptake of biosimilars in Europe and what still needs to be done? The European market for biosimilars has seen a year of progress and change, with more therapies available and changing...
  • Biosimilars in Oncology: KOL Insight
    Learn More Biosimilars in Oncology: KOL Insight
    Will physicians ever adopt Biosimilars in Oncology? Sceptical, survival focussed oncologists that make treatment decisions in life or death situations aren't yet ready to accept biosimilars of proven targeted treatments...
  • Biosimilars: Regulatory Outlook
    Learn More Biosimilars: Regulatory Outlook
    Biosimilars offer a chance to improve access to, and reduce spending on, life-saving biologic therapies. But could regulators do more to support the market? While experts believe significant regulatory progress has been...
  • The Future of Biosimilars 2015
    Learn More The Future of Biosimilars 2015
    The Future of Biosimilars 2015 offers expert insight and opinion on the key issues facing the high risk, high reward biosimilars market: how the market is performing, where the market is headed and which key milestones are...
  • Pages:
  • 1
  • 2

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved